In vivo evidence for an endothelium-dependent mechanism in radiation-induced normal tissue injury

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Rannou, Emilie ^a   François, Agnès ^a   Toullec, Aurore ^a   Guipaud, Olivier ^a   Buard, Valérie ^a   Tarlet, Georges ^a   Mintet, Elodie ^a   Jaillet, Cyprien ^a   Iruela Arispe, Maria Luisa ^b   Benderitter, Marc ^a   Sabourin, Jean Christophe ^c   Milliat, Fabien ^a  

^a INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE IRSN   (France)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEASE NEXIN I; SERPINE2 PROTEIN, MOUSE;

ADVERSE EFFECTS; ANIMAL; CELL SURVIVAL; ENDOTHELIUM; EXPERIMENTAL RADIATION INJURY; GAMMA RADIATION; GENE EXPRESSION REGULATION; GENETICS; INTESTINE; KNOCKOUT MOUSE; METABOLISM; MOUSE; PATHOLOGY; RADIATION RESPONSE;

ANIMALS; CELL SURVIVAL; ENDOTHELIUM; GAMMA RAYS; GENE EXPRESSION REGULATION; INTESTINES; MICE; MICE, KNOCKOUT; RADIATION INJURIES, EXPERIMENTAL; SERPIN E2;

EID: 84946139353     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep15738     Document Type: Article

References (42)

1. Bentzen, S. M. Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer 6, 702-713 (2006).
2. Andreyev, H. J., Wotherspoon, A., Denham, J. W. and Hauer-Jensen, M. Defining pelvic-radiation disease for the survivorship era. Lancet Oncol 11, 310-312 (2010).
3. Hauer-Jensen, M., Denham, J. W. and Andreyev, H. J. Radiation enteropathy-pathogenesis, treatment and prevention. Nat Rev Gastroenterol Hepatol 11, 470-479 (2014).
4. Atwood, K. C. and Norman, A. On the Interpretation of Multi-Hit Survival Curves. Proc Natl Acad Sci USA 35, 696-709 (1949).
5. Baker, D. G. and Krochak, R. J. The response of the microvascular system to radiation: a review. Cancer Invest 7, 287-294 (1989).
6. Wang, J., Boerma, M., Fu, Q. and Hauer-Jensen, M. Significance of endothelial dysfunction in the pathogenesis of early and delayed radiation enteropathy. World J Gastroenterol 13, 3047-3055 (2007).
7. Kohler, H. P. and Grant, P. J. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 342, 1792-1801 (2000).
8. Renckens, R. et al. The role of plasminogen activator inhibitor type 1 in the inflammatory response to local tissue injury. J Thromb Haemost 3, 1018-1025 (2005).
9. Bauman, K. A. et al. The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice. J Clin Invest 120, 1950-1960 (2010).
10. Oda, T. et al. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 60, 587-596 (2001).
11. Osterholzer, J. J. et al. PAI-1 promotes the accumulation of exudate macrophages and worsens pulmonary fibrosis following type II alveolar epithelial cell injury. J Pathol 228, 170-180 (2012).
12. Halle, M., Ekstrom, M., Farnebo, F. and Tornvall, P. Endothelial activation with prothrombotic response in irradiated microvascular recipient veins. J Plast Reconstr Aesthet Surg 63, 1910-1916 (2010).
13. Milliat, F. et al. Essential role of plasminogen activator inhibitor type-1 in radiation enteropathy. Am J Pathol 172, 691-701 (2008).
14. Ebrahimian, T. G. et al. Plasminogen activator inhibitor-1 controls bone marrow-derived cells therapeutic effect through MMP9 signaling: role in physiological and pathological wound healing. Stem Cells 30, 1436-1446 (2012).
15. Qiu, W. et al. PUMA regulates intestinal progenitor cell radiosensitivity and gastrointestinal syndrome. Cell Stem Cell 2, 576-583 (2008).
16. Zheng, H., Wang, J., Koteliansky, V. E., Gotwals, P. J. and Hauer-Jensen, M. Recombinant soluble transforming growth factor beta type II receptor ameliorates radiation enteropathy in mice. Gastroenterology 119, 1286-1296 (2000).
17. Cho, C. H. et al. COMP-Ang1: a designed angiopoietin-1 variant with nonleaky angiogenic activity. Proc Natl Acad Sci USA 101, 5547-5552 (2004).
18. Paris, F. et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293, 293-297 (2001).
19. Rotolo, J. et al. Anti-ceramide antibody prevents the radiation gastrointestinal syndrome in mice. J Clin Invest 122, 1786-1790 (2012).
20. Schuller, B. W. et al. No significant endothelial apoptosis in the radiation-induced gastrointestinal syndrome. Int J Radiat Oncol Biol Phys 68, 205-210 (2007).
21. Schuller, B. W. et al. Selective irradiation of the vascular endothelium has no effect on the survival of murine intestinal crypt stem cells. Proc Natl Acad Sci USA 103, 3787-3792 (2006).
22. Kim, D. W. et al. Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 89, 509-517 (2014).
23. Kirsch, D. G. Using genetically engineered mice for radiation research. Radiat Res 176, 275-279 (2011).
24. Lee, C. L. et al. p53 functions in endothelial cells to prevent radiation-induced myocardial injury in mice. Sci Signal 5, ra52 (2012).
25. Kirsch, D. G. et al. p53 controls radiation-induced gastrointestinal syndrome in mice independent of apoptosis. Science 327, 593-596 (2010).
26. Engelmann, B. and Massberg, S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 13, 34-45 (2013).
27. Wolthuis, E. K. et al. Plasminogen activator inhibitor-type I gene deficient mice show reduced influx of neutrophils in ventilatorinduced lung injury. Crit Care Res Pract 2011, 217896 (2011).
28. Roelofs, J. J. et al. Plasminogen activator inhibitor-1 regulates neutrophil influx during acute pyelonephritis. Kidney Int 75, 52-59 (2009).
29. Park, Y. J. et al. PAI-1 inhibits neutrophil efferocytosis. Proc Natl Acad Sci USA 105, 11784-11789 (2008).
30. Zmijewski, J. W. et al. Inhibition of neutrophil apoptosis by PAI-1. Am J Physiol Lung Cell Mol Physiol 301, L247-254 (2011).
31. Zhao, R., Ren, S., Moghadasain, M. H., Rempel, J. D. and Shen, G. X. Involvement of fibrinolytic regulators in adhesion of monocytes to vascular endothelial cells induced by glycated LDL and to aorta from diabetic mice. J Leukoc Biol 95, 941-949 (2014).
32. Chinetti-Gbaguidi, G., Colin, S. and Staels, B. Macrophage subsets in atherosclerosis. Nat Rev Cardiol 12, 10-17 (2015).
33. Murray, P. J. and Wynn, T. A. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 11, 723-737 (2011).
34. Alva, J. A. et al. VE-Cadherin-Cre-recombinase transgenic mouse: a tool for lineage analysis and gene deletion in endothelial cells. Dev Dyn 235, 759-767 (2006).
35. Monvoisin, A. et al. VE-cadherin-CreERT2 transgenic mouse: a model for inducible recombination in the endothelium. Dev Dyn 235, 3413-3422 (2006).
36. Fink, T., Kazlauskas, A., Poellinger, L., Ebbesen, P. and Zachar, V. Identification of a tightly regulated hypoxia-response element in the promoter of human plasminogen activator inhibitor-1. Blood 99, 2077-2083 (2002).
37. Abderrahmani, R. et al. Effects of pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 in radiation-induced intestinal injury. Int J Radiat Oncol Biol Phys 74, 942-948 (2009).
38. Gorlatova, N. V. et al. Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitor. J Biol Chem 282, 9288-9296 (2007).
39. Boe, A. E. et al. Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nomega-nitro-L-arginine methyl ester-induced hypertension and vascular senescence. Circulation 128, 2318-2324 (2013).
40. Florova, G. et al. Targeting of plasminogen activator inhibitor 1 improves fibrinolytic therapy for tetracycline-induced pleural injury in rabbits. Am J Respir Cell Mol Biol 52, 429-437 (2015).
41. Ibrahim, A. A. et al. Inhibition of plasminogen activator inhibitor type-1 activity enhances rapid and sustainable hematopoietic regeneration. Stem Cells 32, 946-958 (2014).
42. Mestdagh, P. et al. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol 10, R64 (2009).